Destiny Pharma’s capital markets day (CMD) focussed investor attention on the company’s XF platform, primarily cantered around on the company’s lead anti-infective asset, XF-73 nasal. The event hosted Key Opinion Leaders (KOL’s) from the clinical community who all conveyed a clear message of the current lack of treatment diversity beyond antibiotics and the burden of antibiotic resistance. The CMD coincided with the release of new positive data for XF-73, news which generated an extremely positi ....
